Clinically tested drugs for Alzheimer's disease (Q35164747)

6 August 2017

1 reference

title

Clinically tested drugs for Alzheimer's disease (English)

1 reference

6 August 2017

0 references

Edith G McGeer

1

1 reference

6 August 2017

Patrick L McGeer

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

1143-1151

1 reference

Neocortical cholinergic neurons in elderly people

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Metrifonate treatment of AD: influence of APOE genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Treatment trial of oxiracetam in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Is there a future for vaccination as a treatment for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Production of superoxide anions by a CNS macrophage, the microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Denbufylline in dementia: a double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.12.7.1143

10.1517/13543784.12.7.1143

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference